



AMCP Urges HHS to Extend Medicare Part D Enhanced MTM Model

On July 28, AMCP signed a Medicare Part D stakeholder letter urging HHS to extend the Enhanced Medication Therapy Management (EMTM) Model which is currently set to expire on Dec. 31, 2021. Continuing the Model will allow evaluators to better understand the full savings and quality improvement implications of the first five years of the Model, without disrupting current programs and investments. The stakeholders also suggested that HHS apply key flexibilities from the Model to the national Part D MTMP, to allow plan sponsors to implement innovative best practices currently unavailable in MTMP.

[Read the letter.](#)

This is a promotional banner for Kerendia (finerenone) tablets. On the left is the Bayer logo. Next to it, the text "Now approved" is written in a bold, sans-serif font. To the right is the Kerendia logo, which consists of a stylized red and grey swirl, followed by the text "Kerendia® (finerenone) tablets" and "10 mg • 20 mg" below it. On the far right, there is a grey button with the text "Learn more about KERENDIA" and a red arrow pointing to the right. At the bottom right, in small text, it says "© 2021 Bayer. All rights reserved. BAYER, the Bayer Cross, and KERENDIA are registered trademarks of Bayer. PP-FINE-US-0601-1 07/21".

Eye On Washington

Biden Administration Withdraws the Most Favored Nations Model

On Aug. 10, the Biden administration rescinded the Most Favored Nations Model interim final rule, ending the possibility that it would be implemented. This would have been a mandatory, nationwide model that would calculate the payment rate for certain Medicare Part B drugs based on the price paid in other countries. The model was issued by the Trump administration without going through the proper rulemaking process and as such, was blocked from implementation in January by the courts in response to four separate lawsuits. The Biden administration has now rescinded this rule, though it does indicate that it is open to pursuing models to address high Part B drug costs.

[Read the Federal Register notice.](#)

Advocacy Tip

Stay up-to-date: Read AMCP's [Letters, Statements and Analysis](#) on all legislation and regulation impacting managed care pharmacy.

AMCP Supports FDA Approval of Biosimilar Insulin

On July 29, AMCP released a statement applauding the FDA's approval of the first interchangeable biosimilar insulin product. This approval allows pharmacists to substitute biosimilar insulin for the innovator insulin at the pharmacy counter for the first time. This means that more people will be able to access insulin products, resulting in better care at a lower cost.

[Read AMCP's statement.](#)

President Biden Calls on Congress to Reduce Drug Prices

On Aug. 12, the White House released a fact sheet detailing President Biden's vision to lower the cost of prescription drugs. The president also delivered a related speech advocating for Congress to pursue the following measures: allowing Medicare to negotiate prices, specifically for drugs without competition; penalties for pharmaceutical companies whose prices rise faster than inflation; and establishing annual caps on the amount Medicare beneficiaries pay out-of-pocket for prescriptions.

[Read the fact sheet.](#)

[Read a transcript of President Biden's remarks.](#)



Now approved



Learn more
about KERENDIA >

© 2021 Bayer. All rights reserved.
BAYER, the Bayer Cross, and
KERENDIA are registered trademarks
of Bayer. PP-FINE-US-0689-1 07/21

AMCP

675 North Washington Street, Suite 220, Alexandria, VA 22314
703.684.2600 | www.amcp.org

[Manage My Emails](#)